Cancer Heterogeneity and Cancer Cell Plasticity: Molecular Mechanisms and Precision Therapy

Abstract

Tumor heterogeneity creates selective pressures and ecological niches that enable cancer cell plasticity; conversely, plasticity continuously generates and reshapes heterogeneity. Together, these processes drive tumor progression, therapeutic resistance, recurrence, and divergent clinical outcomes, thereby limiting the durability of precision oncology. In this Review, we synthesize recent advances in our understanding tumor heterogeneity and cancer cell plasticity across spatial, temporal, and molecular scales, and discuss how the tumor microenvironment regulates plasticity through physical, chemical, and biological cues. We further outline three fundamental challenges for precision therapy, namely, target loss, bypass pathway activation, and adaptive cell-state transitions, and argue that drug resistance is critically shaped by cancer cell plasticity, which varies widely among patients and contributes to heterogeneous therapeutic efficacy. Building on this framework, we propose a next-generation precision-oncology paradigm integrating stratified diagnosis, rational combination intervention, and adaptive monitoring. Finally, we discuss how the integration of single-cell and spatial multiomics, together with artificial intelligence, could enable the development of “digital twin” tumor models to guide individualized therapeutic decision-making. Collectively, this review provides an integrated conceptual foundation and practical roadmap for overcoming key bottlenecks in precision oncology driven by tumor heterogeneity and cancer cell plasticity.

Keywords

cancer cell plasticity / precision oncology / therapeutic resistance / tumor heterogeneity / tumor microenvironment

References

[1] J. Kocarnik, “Cancer's Global Epidemiological Transition and Growth,” Lancet 395, no. 10226 (2020): 757–758.

[2] F. Bray, A. Jemal, N. Grey, J. Ferlay, and D. Forman, “Global Cancer Transitions According to the Human Development Index (2008-2030): A Population-Based Study,” The Lancet Oncology 13, no. 8 (2012): 790–801.

[3] S. Yuan, R. J. Norgard, and B. Z. Stanger, “Cellular Plasticity in Cancer,” Cancer Discovery 9, no. 7 (2019): 837–851.

[4] J. B. Finlay, A. S. Ireland, S. B. Hawgood, et al., “Olfactory Neuroblastoma Mimics Molecular Heterogeneity and Lineage Trajectories of Small-Cell Lung Cancer,” Cancer Cell 42, no. 6 (2024): 1086–1105.e13.

[5] E. A. Oliveira, S. Milite, J. Fernandez-Mateos, et al., “Epigenetic Heritability of Cell Plasticity Drives Cancer Drug Resistance Through a One-to-Many Genotype-to-Phenotype Paradigm,” Cancer Research 85, no. 15 (2025): 2921–2938.

[6] N. Naithani, A. T. Atal, T. Tilak, B. Vasudevan, P. Misra, and S. Sinha, “Precision Medicine: Uses and Challenges,” Medical Journal Armed Forces India 77, no. 3 (2021): 258–265.

[7] M. Roszkowska, “Multilevel Mechanisms of Cancer Drug Resistance,” International Journal of Molecular Sciences 25, no. 22 (2024): 12402.

[8] A. Marusyk, M. Janiszewska, and K. Polyak, “Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance,” Cancer Cell 37, no. 4 (2020): 471–484.

[9] L. Keller and K. Pantel, “Unravelling Tumour Heterogeneity by Single-Cell Profiling of Circulating Tumour Cells,” Nature Reviews Cancer 19, no. 10 (2019): 553–567.

[10] J. S. Parker and C. M. Perou, “Tumor Heterogeneity: Focus on the Leaves, the Trees, or the Forest?,” Cancer Cell 28, no. 2 (2015): 149–150.

[11] L. De Mattos-Arruda, B. Weigelt, J. Cortes, et al., “Capturing Intra-Tumor Genetic Heterogeneity by De Novo Mutation Profiling of Circulating Cell-Free Tumor DNA: A Proof-of-Principle,” Annals of Oncology 25, no. 9 (2014): 1729–1735.

[12] K. E. de Visser and J. A. Joyce, “The Evolving Tumor Microenvironment: From Cancer Initiation to Metastatic Outgrowth,” Cancer Cell 41, no. 3 (2023): 374–403..

[13] E. Zheng, P. Madura, J. Grandos, et al., “When the Same Treatment Has Different Response: The Role of Pharmacogenomics in Statin Therapy,” Biomedicine & Pharmacotherapy 170 (2024): 115966.

[14] S. Plunder, C. Danesin, B. Glise, M. A. Ferreira, S. Merino-Aceituno, and E. Theveneau, “Modelling Variability and Heterogeneity of EMT Scenarios Highlights Nuclear Positioning and Protrusions as Main Drivers of Extrusion,” Nature Communications 15, no. 1 (2024): 7365.

[15] J. Chen, L. Larsson, A. Swarbrick, and J. Lundeberg, “Spatial Landscapes of Cancers: Insights and Opportunities,” Nature Reviews Clinical Oncology 21, no. 9 (2024): 660–674.

[16] L. Xiang, K. Chen, R. Yan, W. Li, and K. Xu, “Single-Molecule Displacement Mapping Unveils Nanoscale Heterogeneities in Intracellular Diffusivity,” Nature Methods 17, no. 5 (2020): 524–530.

[17] I. Dagogo-Jack and A. T. Shaw, “Tumour Heterogeneity and Resistance to Cancer Therapies,” Nature Reviews Clinical Oncology 15, no. 2 (2018): 81–94.

[18] L. Desharnais, M. Sorin, M. Rezanejad, et al., “Spatially Mapping the Tumour Immune Microenvironments of Non-Small Cell Lung Cancer,” Nature Communications 16, no. 1 (2025): 1345.

[19] M. Allam, T. Hu, J. Lee, et al., “Spatially Variant Immune Infiltration Scoring in Human Cancer Tissues,” npj Precision Oncology 6, no. 1 (2022): 60.

[20] J. Le, Y. Dian, D. Zhao, et al., “Single-Cell Multi-Omics in Cancer Immunotherapy: From Tumor Heterogeneity to Personalized Precision Treatment,” Molecular Cancer 24, no. 1 (2025): 221.

[21] M. Cieslik and A. M. Chinnaiyan, “Global Genomics Project Unravels Cancer's Complexity at Unprecedented Scale,” Nature 578, no. 7793 (2020): 39–40.

[22] R. Khamsi, “Computing Cancer's Weak Spots,” Science 368, no. 6496 (2020): 1174–1177.

[23] B. Losic, A. J. Craig, C. Villacorta-Martin, et al., “Intratumoral Heterogeneity and Clonal Evolution in Liver Cancer,” Nature Communications 11, no. 1 (2020): 291.

[24] N. Elazab, F. Khalifa, W. Gab Allah, and M. Elmogy, “Histopathological-Based Brain Tumor Grading Using 2D-3D Multi-Modal CNN-Transformer Combined With Stacking Classifiers,” Scientific Reports 15, no. 1 (2025): 27764.

[25] H. J. Burstein, G. Curigliano, B. Thurlimann, et al., “Customizing Local and Systemic Therapies for Women With Early Breast Cancer: The St. Gallen International Consensus Guidelines for Treatment of Early Breast Cancer 2021,” Annals of Oncology 32, no. 10 (2021): 1216–1235.

[26] L. A. Huppert, O. Gumusay, D. Idossa, and H. S. Rugo, “Systemic Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Stage and Metastatic Breast Cancer,” CA: A Cancer Journal for Clinicians 73, no. 5 (2023): 480–515..

[27] Y. Loriot, M. Kamal, L. Syx, et al., “The Genomic and Transcriptomic Landscape of Metastastic Urothelial Cancer,” Nature Communications 15, no. 1 (2024): 8603.

[28] V. Vijay, N. Karisani, L. Shi, et al., “Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets,” Cancer Discovery 15, no. 9 (2025): 1858–1882.

[29] H. X. Wu, Y. K. Chen, Y. N. Wang, et al., “Dissecting Small Cell Carcinoma of the Esophagus Ecosystem by Single-Cell Transcriptomic Analysis,” Molecular Cancer 24, no. 1 (2025): 142.

[30] S. Neyazi, E. Yamazawa, K. Hack, et al., “Transcriptomic and Epigenetic Dissection of Spinal Ependymoma (SP-EPN) Identifies Clinically Relevant Subtypes Enriched for Tumors With and Without NF2 Mutation,” Acta Neuropathologica 147, no. 1 (2024): 22.

[31] D. R. Ghasemi, M. Sill, K. Okonechnikov, et al., “MYCN Amplification Drives an Aggressive Form of Spinal Ependymoma,” Acta Neuropathologica 138, no. 6 (2019): 1075–1089.

[32] K. Hack, S. L. Jauch-Speer, C. Kresbach, M. Schoof, C. Thomas, and U. Schuller, “Single-Nucleus Transcriptomics of Spinal Ependymoma Subtypes Recognizes Intratumoral Heterogeneity,” Neuro-Oncology 28, no. 1 (2025): 86–98.

[33] X. Chu, X. Li, Y. Zhang, et al., “Integrative Single-Cell Analysis of Human Colorectal Cancer Reveals Patient Stratification With Distinct Immune Evasion Mechanisms,” Nature Cancer 5, no. 9 (2024): 1409–1426.

[34] B. A. Helmink, S. M. Reddy, J. Gao, et al., “B Cells and Tertiary Lymphoid Structures Promote Immunotherapy Response,” Nature 577, no. 7791 (2020): 549–555.

[35] J. L. Teillaud, A. Houel, M. Panouillot, C. Riffard, and M. C. Dieu-Nosjean, “Tertiary Lymphoid Structures in Anticancer Immunity,” Nature Reviews Cancer 24, no. 9 (2024): 629–646.

[36] F. Petitprez, A. de Reynies, E. Z. Keung, et al., “B Cells Are Associated With Survival and Immunotherapy Response in Sarcoma,” Nature 577, no. 7791 (2020): 556–560.

[37] C. Sautes-Fridman, F. Petitprez, J. Calderaro, and W. H. Fridman, “Tertiary Lymphoid Structures in the Era of Cancer Immunotherapy,” Nature Reviews Cancer 19, no. 6 (2019): 307–325.

[38] M. Amisaki, A. Zebboudj, H. Yano, et al., “IL-33-Activated ILC2s Induce Tertiary Lymphoid Structures in Pancreatic Cancer,” Nature 638, no. 8052 (2025): 1076–1084.

[39] Z. Tang, Y. Bai, Q. Fang, et al., “Spatial Transcriptomics Reveals Tryptophan Metabolism Restricting Maturation of Intratumoral Tertiary Lymphoid Structures,” Cancer Cell 43, no. 6 (2025): 1025–1044.e14.

[40] K. S. S. Enfield, E. Colliver, C. Lee, et al., “Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer,” Cancer Discovery 14, no. 6 (2024): 1018–1047.

[41] C. Ruiz-Moreno, S. M. Salas, E. Samuelsson, et al., “Charting the Single-Cell and Spatial Landscape of IDH-Wild-Type Glioblastoma With GBmap,” Neuro-Oncology 27, no. 9 (2025): 2281–2295.

[42] H. Chen, C. Deng, J. Gao, et al., “Integrative Spatial Analysis Reveals Tumor Heterogeneity and Immune Colony Niche Related to Clinical Outcomes in Small Cell Lung Cancer,” Cancer Cell 43, no. 3 (2025): 519–536.e5.

[43] G. Espinosa-Carrasco, E. Chiu, A. Scrivo, et al., “Intratumoral Immune Triads Are Required for Immunotherapy-Mediated Elimination of Solid Tumors,” Cancer Cell 42, no. 7 (2024): 1202–1216.e8.

[44] W. Su, Z. Ye, J. Liu, et al., “Single-Cell and Spatial Transcriptome Analyses Reveal Tumor Heterogeneity and Immune Remodeling Involved in Pituitary Neuroendocrine Tumor Progression,” Nature Communications 16, no. 1 (2025): 5007.

[45] A. Contreras-Sanz, G. L. Negri, M. J. Reike, et al., “Proteomic Profiling Identifies Muscle-Invasive Bladder Cancers With Distinct Biology and Responses to Platinum-Based Chemotherapy,” Nature Communications 16, no. 1 (2025): 1240.

[46] Z. Zhang, Z. Zhang, Y. Zhang, et al., “Phosphoproteomics Delineates Hepatocellular Carcinoma Subtypes and Pinpoints Therapeutic Targets,” Hepatology 82, no. 6 (2025): 1432–1449.

[47] L. Meyer, H. W. Jackson, N. Eling, et al., “A Stratification System for Breast Cancer Based on Basoluminal Tumor Cells and Spatial Tumor Architecture,” Cancer Cell 43, no. 9 (2025): 1637–1655.e9.

[48] X. Sun, J. Xia, H. Jiang, et al., “Single-Cell and Spatial Transcriptome Profiling Identifies Cellular Heterogeneity and Immunosuppressive Tumor Microenvironment in Inflammatory Breast Cancer,” Journal of Advanced Research 81 (2025): 637–656.

[49] S. Satpathy, N. M. Clark, Y. J. Chen, et al., “Integrative Analysis of Lung Adenocarcinoma Across Diverse Ethnicities and Exposures,” Cancer Cell 43, no. 9 (2025): 1731–1757.e17.

[50] J. Zhao, M. Shen, X. Xu, et al., “Proteomics and Single Cell Profiling Identify Keratin Driven Preexisting Immunity Influences Lung Squamous Carcinoma Neoadjuvant Therapy,” Cancer Letters 633 (2025): 218000.

[51] P. Yu, C. Hu, G. Ding, et al., “Mutation Characteristics and Molecular Evolution of Ovarian Metastasis From Gastric Cancer and Potential Biomarkers for Paclitaxel Treatment,” Nature Communications 15, no. 1 (2024): 3771.

[52] Y. Totoki, M. Saito-Adachi, Y. Shiraishi, et al., “Multiancestry Genomic and Transcriptomic Analysis of Gastric Cancer,” Nature Genetics 55, no. 4 (2023): 581–594.

[53] W. S. Lee, S. Woo, S. H. Lee, et al., “Integrative Multi-Omics Profiling Identifies Infiltrative Hepatocellular Carcinoma as an Immunotherapy-Resistant Subtype With Distinct Molecular Features,” Clinical and Molecular Hepatology 32, no. 1 (2026): 258–275.

[54] X. Rong, J. Guan, C. Ye, et al., “SPINK1-Driven Cellular Heterogeneity and Interaction Networks in Intrahepatic Cholangiocarcinoma Revealed by Integrated Multi-Omics Analysis,” Journal of Advanced Research (2025).

[55] A. H. Nassar, C. Kim, T. Adeyelu, et al., “Integrated Molecular and Clinical Characterization of Pulmonary Large Cell Neuroendocrine Carcinoma,” Nature Communications 16, no. 1 (2025): 7717.

[56] Y. Ying, H. Wang, Y. Wang, et al., “PPIF(+) Neutrophils Promote mtROS Driven NETosis Mediated Progression of Colorectal Cancer,” Journal of Translational Medicine 23, no. 1 (2025): 1259.

[57] H. Li, L. Lan, H. Chen, et al., “SPP1 is Required for Maintaining Mesenchymal Cell Fate in Pancreatic Cancer,” Nature 648, no. 8092 (2025): 203–209.

[58] P. Di Chiaro, L. Nacci, F. Arco, et al., “Mapping Functional to Morphological Variation Reveals the Basis of Regional Extracellular Matrix Subversion and Nerve Invasion in Pancreatic Cancer,” Cancer Cell 42, no. 4 (2024): 662–681.e10.

[59] R. Rothe, A. Tunger, T. Link, et al., “Multi-Compartment Immune Cell Profiling Highlights the Prognostic Relevance of CD127+ CD8+ T Cells for Patients With High-Grade Serous Ovarian Cancer,” Frontiers in Immunology 16 (2025): 1607471.

[60] G. Micoli, K. Lavikka, Y. Li, et al., “Decoding the Genomic and Functional Landscape of Emerging Subtypes in Ovarian Cancer,” Cancer Discovery 15, no. 11 (2025): 2262–2277.

[61] X. Li, K. Singhal, Q. Deng, et al., “Large B Cell Lymphoma Microenvironment Archetype Profiles,” Cancer Cell 43, no. 7 (2025): 1347–1364.e13.

[62] Y. Q. Li, C. L. Luo, J. X. Jiang, et al., “Single-Cell Analysis Reveals Malignant Cells Reshape the Cellular Landscape and Foster an Immunosuppressive Microenvironment of Extranodal NK/T-Cell Lymphoma,” Advanced Science (Weinheim, Baden-Wurttemberg, Germany) 10, no. 36 (2023): e2303913.

[63] Y. Li, Z. Cui, X. Song, et al., “Single-Cell Transcriptomic Landscape Deciphers Intratumoral Heterogeneity and Subtypes of Acral and Mucosal Melanomas,” Clinical Cancer Research 31, no. 12 (2025): 2495–2514.

[64] T. Minowa, K. Murata, Y. Mizue, et al., “Single-Cell Profiling of Acral Melanoma Infiltrating Lymphocytes Reveals a Suppressive Tumor Microenvironment,” Science Translational Medicine 16, no. 776 (2024): eadk8832.

[65] M. P. Roudier, R. Gulati, E. Sayar, et al., “Patterns of Intra- and Intertumor Phenotypic Heterogeneity in Lethal Prostate Cancer,” Journal of Clinical Investigation 135, no. 15 (2025): e186599.

[66] X. Bian, W. Wang, M. Abudurexiti, et al., “Integration Analysis of Single-Cell Multi-Omics Reveals Prostate Cancer Heterogeneity,” Advanced Science (Weinheim, Baden-Wurttemberg, Germany) 11, no. 18 (2024): e2305724.

[67] Y. Shi, K. An, and Y. Qi, “A Single-Cell and Spatially Resolved Cell Atlas of Human Esophageal Squamous Cell Carcinoma,” Genomics, Proteomics & Bioinformatics (2025).

[68] G. Jiang, Z. Wang, Z. Cheng, et al., “The Integrated Molecular and Histological Analysis Defines Subtypes of Esophageal Squamous Cell Carcinoma,” Nature Communications 15, no. 1 (2024): 8988.

[69] J. Seok, H. Choi, E. K. Lee, et al., “Tumor Microenvironment Remodeling Across Thyroid Cancer Differentiation States Revealed by Spatial Transcriptomics,” Cancer Immunology, Immunotherapy 74, no. 12 (2025): 357.

[70] K. Guo, L. Yang, Z. Huang, et al., “Single-Cell RNA Sequencing Reveals the Heterogeneity in Differentiation Trajectory and Tumor Microenvironment Leading to More Aggressive Phenotypes of Papillary Thyroid Cancer in Children and Young Adult Patients,” Advanced Science (Weinheim, Baden-Wurttemberg, Germany) 12, no. 39 (2025): e17672.

[71] E. O. Karakaslar, E. M. Argiro, N. E. Struckman, et al., “Resolving Inter- and Intra-Patient Heterogeneity in NPM1-Mutated AML at Single-Cell Resolution,” Leukemia 39, no. 12 (2025): 2916–2925.

[72] W. Y. Cheng, X. Yi, Z. Y. Wang, et al., “Proteomic Subtypes Enrich Current Acute Myeloid Leukemia Nomenclature and Reflect Intrinsic Pathogenesis Alongside Aging,” Blood 146, no. 22 (2025): 2681–2695.

[73] T. Mazor, A. Pankov, J. S. Song, and J. F. Costello, “Intratumoral Heterogeneity of the Epigenome,” Cancer Cell 29, no. 4 (2016): 440–451.

[74] M. Eisenstein, “Reading Cancer's Blueprint,” Nature Biotechnology 30, no. 7 (2012): 581–584.

[75] C. K. Mo, J. Liu, S. Chen, et al., “Tumour Evolution and Microenvironment Interactions in 2D and 3D Space,” Nature 634, no. 8036 (2024): 1178–1186.

[76] F. He, A. M. Bandyopadhyay, L. J. Klesse, et al., “Genomic Profiling of Subcutaneous Patient-Derived Xenografts Reveals Immune Constraints on Tumor Evolution in Childhood Solid Cancer,” Nature Communications 14, no. 1 (2023): 7600.

[77] L. Wang, H. Geng, Y. Liu, et al., “Hot and Cold Tumors: Immunological Features and the Therapeutic Strategies,” MedComm 4, no. 5 (2023): e343.

[78] K. Coleman, A. Schroeder, M. Loth, et al., “Resolving Tissue Complexity by Multimodal Spatial Omics Modeling With MISO,” Nature Methods 22, no. 3 (2025): 530–538.

[79] F. Martinez-Jimenez, A. Movasati, S. R. Brunner, et al., “Pan-Cancer Whole-Genome Comparison of Primary and Metastatic Solid Tumours,” Nature 618, no. 7964 (2023): 333–341.

[80] F. Martínez-Jiménez, A. Movasati, S. R. Brunner, et al., “Pan-Cancer Whole-Genome Comparison of Primary and Metastatic Solid Tumours,” Nature 618, no. 7964 (2023): 333–341.

[81] L. Zhong, Z. Zhao, and X. Zhang, “Genetic Differences Between Primary and Metastatic Cancer: A Pan-Cancer Whole-Genome Comparison Study,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 363.

[82] Y. Sun, P. Wu, Z. Zhang, et al., “Integrated Multi-Omics Profiling to Dissect the Spatiotemporal Evolution of Metastatic Hepatocellular Carcinoma,” Cancer Cell 42, no. 1 (2024): 135–156.e17.

[83] U. Singhal, S. Nallandhighal, J. J. Tosoian, et al., “Integrative Multi-Region Molecular Profiling of Primary Prostate Cancer in Men With Synchronous Lymph Node Metastasis,” Nature Communications 15, no. 1 (2024): 4341.

[84] E. W. Warner, K. Van der Eecken, A. J. Murtha, et al., “Multiregion Sampling of De Novo Metastatic Prostate Cancer Reveals Complex Polyclonality and Augments Clinical Genotyping,” Nature Cancer 5, no. 1 (2024): 114–130.

[85] C. J. Ong, J. J. Zhao, Y. Liu, et al., “Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis,” Clinical Cancer Research 31, no. 12 (2025): 2515–2529.

[86] R. Li, X. Liu, X. Huang, et al., “Single-Cell Transcriptomic Analysis Deciphers Heterogenous Cancer Stem-Like Cells in Colorectal Cancer and Their Organ-Specific Metastasis,” Gut 73, no. 3 (2024): 470–484.

[87] C. Zhou, S. Shan, L. Wen, et al., “Immunological and Pathological Characteristics of Brain Parenchymal and Leptomeningeal Metastases From Non-Small Cell Lung Cancer,” Cell Discovery 11, no. 1 (2025): 72.

[88] D. Restle, J. Dux, X. Li, et al., “Organ-Specific Heterogeneity in Tumor-Infiltrating Immune Cells and Cancer Antigen Expression in Primary and Autologous Metastatic Lung Adenocarcinoma,” Journal for ImmunoTherapy of Cancer 11, no. 6 (2023): e006609.

[89] Y. Zhang, R. Cheng, T. Ding, and J. Wu, “Discrepancies in PD-L1 Expression, Lymphocyte Infiltration, and Tumor Mutational Burden in Non-Small Cell Lung Cancer and Matched Brain Metastases,” Translational Lung Cancer Research 13, no. 12 (2024): 3590–3602.

[90] G. Pei, J. Min, and K. I. Rajapakshe, “Spatial Mapping of Transcriptomic Plasticity in Metastatic Pancreatic Cancer,” Nature 642, no. 8066 (2025): 212–221.

[91] L. Kuett, A. Bollhagen, S. Tietscher, et al., “Distant Metastases of Breast Cancer Resemble Primary Tumors in Cancer Cell Composition but Differ in Immune Cell Phenotypes,” Cancer Research 85, no. 1 (2025): 15–31.

[92] S. Mirzaei, M. D. A. Paskeh, M. Entezari, et al., “SOX2 Function in Cancers: Association With Growth, Invasion, Stemness and Therapy Response,” Biomedicine & Pharmacotherapy 156 (2022): 113860.

[93] R. Strauss, P. Hamerlik, A. Lieber, and J. Bartek, “Regulation of Stem Cell Plasticity: Mechanisms and Relevance to Tissue Biology and Cancer,” Molecular Therapy 20, no. 5 (2012): 887–897.

[94] Y. Cheng, L. Bai, and J. Cui, “Harnessing Multi-Omics Approaches to Decipher Tumor Evolution and Improve Diagnosis and Therapy in Lung Cancer,” Biomarker Research 13, no. 1 (2025): 140.

[95] M. Nikanjam and R. Kurzrock, “Cracking the Resistance Code: The Molecular Reclassification of Cancer and Precision Therapy Strategies,” Seminars in Cancer Biology 117 (2025): 57–68.

[96] K. K. Huang, H. Ma, R. H. H. Chong, et al., “Spatiotemporal Genomic Profiling of Intestinal Metaplasia Reveals Clonal Dynamics of Gastric Cancer Progression,” Cancer Cell 41, no. 12 (2023): 2019–2037.e8.

[97] W. Xian, S. Wang, J. Xie, et al., “Evolution of Esophageal Adenocarcinoma From Precursor Lesion Stem Cells,” Gastroenterology 169, no. 2 (2025): 277–293.e4.

[98] A. M. Braxton, A. L. Kiemen, M. P. Grahn, et al., “3D Genomic Mapping Reveals Multifocality of Human Pancreatic Precancers,” Nature 629, no. 8012 (2024): 679–687.

[99] C. N. Heiser, A. J. Simmons, F. Revetta, et al., “Molecular Cartography Uncovers Evolutionary and Microenvironmental Dynamics in Sporadic Colorectal Tumors,” Cell 186, no. 25 (2023): 5620–5637.e16.

[100] M. Dang, R. Wang, H. C. Lee, et al., “Single Cell Clonotypic and Transcriptional Evolution of Multiple Myeloma Precursor Disease,” Cancer Cell 41, no. 6 (2023): 1032–1047.e4.

[101] J. H. Choi, B. S. Lee, J. Y. Jang, et al., “Single-Cell Transcriptome Profiling of the Stepwise Progression of Head and Neck Cancer,” Nature Communications 14, no. 1 (2023): 1055.

[102] T. Nishimura, N. Kakiuchi, K. Yoshida, et al., “Evolutionary Histories of Breast Cancer and Related Clones,” Nature 620, no. 7974 (2023): 607–614.

[103] R. Mathur, Q. Wang, P. G. Schupp, et al., “Glioblastoma Evolution and Heterogeneity From a 3D Whole-Tumor Perspective,” Cell 187, no. 2 (2024): 446–463.e16.

[104] A. M. Frankell, M. Dietzen, and M. Al Bakir, “The Evolution of Lung Cancer and Impact of Subclonal Selection in TRACERx,” Nature 616, no. 7957 (2023): 525–533.

[105] J. George, L. Maas, N. Abedpour, et al., “Evolutionary Trajectories of Small Cell Lung Cancer Under Therapy,” Nature 627, no. 8005 (2024): 880–889.

[106] J. K. Sabari, B. H. Lok, J. H. Laird, J. T. Poirier, and C. M. Rudin, “Unravelling the Biology of SCLC: Implications for Therapy,” Nature Reviews Clinical Oncology 14, no. 9 (2017): 549–561.

[107] E. H. Ervin, R. French, C. H. Chang, and S. Pauklin, “Inside the Stemness Engine: Mechanistic Links Between Deregulated Transcription Factors and Stemness in Cancer,” Seminars in Cancer Biology 87 (2022): 48–83.

[108] J. Pozniak, D. Pedri, E. Landeloos, et al., “A TCF4-Dependent Gene Regulatory Network Confers Resistance to Immunotherapy in Melanoma,” Cell 187, no. 1 (2024): 166–183.e25.

[109] T. Sheng, R. Sundar, S. Srivastava, et al., “Spatial Profiling of Patient-Matched HER2 Positive Gastric Cancer Reveals Resistance Mechanisms to Targeted Therapy,” Gut 75, no. 4 (2025): 733–747.

[110] K. Mizuno, S. Y. Ku, V. B. Venkadakrishnan, et al., “Intraindividual Epigenetic Heterogeneity Underlying Phenotypic Subtypes of Advanced Prostate Cancer,” Nature Communications 16, no. 1 (2025): 5543.

[111] J. Schiantarelli, M. Benamar, J. Park, et al., “Genomic Mediators of Acquired Resistance to Immunotherapy in Metastatic Melanoma,” Cancer Cell 43, no. 2 (2025): 308–316.e6.

[112] W. Liu, W. You, Z. Lan, et al., “An Immune Cell Map of Human Lung Adenocarcinoma Development Reveals an Anti-Tumoral Role of the Tfh-Dependent Tertiary Lymphoid Structure,” Cell Reports Medicine 5, no. 3 (2024): 101448.

[113] T. Karakousi, T. Mudianto, and A. W. Lund, “Lymphatic Vessels in the Age of Cancer Immunotherapy,” Nature Reviews Cancer 24, no. 6 (2024): 363–381.

[114] C. R. Vakoc and D. A. Tuveson, “Untangling the Genetics From the Epigenetics in Pancreatic Cancer Metastasis,” Nature Genetics 49, no. 3 (2017): 323–324.

[115] Y. Zhang, L. Chang, Y. Yang, et al., “Intratumor Heterogeneity Comparison Among Different Subtypes of Non-Small-Cell Lung Cancer Through Multi-Region Tissue and Matched ctDNA Sequencing,” Molecular Cancer 18, no. 1 (2019): 7.

[116] F. Gimeno-Valiente, C. Castignani, E. Larose Cadieux, et al., “DNA Methylation Cooperates With Genomic Alterations During Non-Small Cell Lung Cancer Evolution,” Nature Genetics 57, no. 9 (2025): 2226–2237.

[117] R. Hablesreiter, P. M. Strzelecka, K. Kopp, et al., “Resolving Intra-Tumor Heterogeneity and Clonal Evolution of Core-Binding Factor Acute Myeloid Leukemia Patients With Single-Cell Resolution,” Experimental Hematology & Oncology 14, no. 1 (2025): 127.

[118] M. Schwede, K. Jahn, J. Kuipers, et al., “Mutation Order in Acute Myeloid Leukemia Identifies Uncommon Patterns of Evolution and Illuminates Phenotypic Heterogeneity,” Leukemia 38, no. 7 (2024): 1501–1510.

[119] A. Weiss, J. Teply-Szymanski, M. Schmitt, et al., “Exploring Intratumoral Heterogeneity in Mixed Neuroendocrine-Nonneuroendocrine Neoplasms With Spatial Transcriptomics: Even More Diverse Than Anticipated,” Endocrine Pathology 36, no. 1 (2025): 29.

[120] N. Soni, K. Rawat, Z. Chen, et al., “Single-Cell Dissection of the Genotype-Immunophenotype Relationship in Glioblastoma,” Brain 148, no. 9 (2025): 3153–3169.

[121] K. McCastlain, C. Welsh, Y. Ni, et al., “Somatic mtDNA Mutations at Intermediate Levels of Heteroplasmy Are a Source of Functional Heterogeneity Among Primary Leukemic Cells,” Science Advances 11, no. 37 (2025): eadt3873.

[122] Q. Wang, J. Wang, R. Mathur, et al., “Spatial 3D Genome Organization Reveals Intratumor Heterogeneity in Primary Glioblastoma Samples,” Science Advances 11, no. 11 (2025): eadn2830.

[123] C. Y. Wu, J. Rong, A. Sathe, et al., “Cancer Subclone Detection Based on DNA Copy Number in Single-Cell and Spatial Omic Sequencing Data,” Nature Methods 22, no. 9 (2025): 1846–1856.

[124] A. Panagopoulos, M. Stout, S. Kilic, et al., “Multigenerational Cell Tracking of DNA Replication and Heritable DNA Damage,” Nature 642, no. 8068 (2025): 785–795.

[125] L. Perelli, L. Zhang, S. Mangiameli, et al., “Evolutionary Fingerprints of Epithelial-To-Mesenchymal Transition,” Nature 640, no. 8060 (2025): 1083–1092.

[126] Y. Xiao, W. Jin, and K. Qian, “Integrative Single Cell Atlas Revealed Intratumoral Heterogeneity Generation From an Adaptive Epigenetic Cell State in Human Bladder Urothelial Carcinoma,” Advanced Science (Weinheim, Baden-Wurttemberg, Germany) 11, no. 24 (2024): e2308438.

[127] Y. J. Huo, S. Cheng, H. M. Yi, et al., “Molecular Heterogeneity of CD30(+) Peripheral T-Cell Lymphoma With Prognostic Significance and Therapeutic Implications: A Retrospective Multi-Centre Study,” EBioMedicine 115 (2025): 105693.

[128] R. A. Hlady, X. Zhao, and L. Y. El Khoury, “Epigenetic Heterogeneity Hotspots in Human Liver Disease Progression,” Hepatology 81, no. 4 (2025): 1197–1210.

[129] A. S. Agustinus, D. Al-Rawi, B. Dameracharla, et al., “Epigenetic Dysregulation From Chromosomal Transit in Micronuclei,” Nature 619, no. 7968 (2023): 176–183.

[130] X. Wang, Q. Sun, T. Liu, et al., “Single-Cell Multi-Omics Sequencing Uncovers Region-Specific Plasticity of Glioblastoma for Complementary Therapeutic Targeting,” Science Advances 10, no. 47 (2024): eadn4306.

[131] P. Smirnov, M. J. Przybilla, M. Simovic-Lorenz, et al., “Multi-Omic and Single-Cell Profiling of Chromothriptic Medulloblastoma Reveals Genomic and Transcriptomic Consequences of Genome Instability,” Nature Communications 15, no. 1 (2024): 10183.

[132] M. Salvadores and F. Supek, “Cell Cycle Gene Alterations Associate With a Redistribution of Mutation Risk Across Chromosomal Domains in Human Cancers,” Nature Cancer 5, no. 2 (2024): 330–346.

[133] L. F. Spurr, C. A. Martinez, W. Kang, et al., “Highly Aneuploid Non-Small Cell Lung Cancer Shows Enhanced Responsiveness to Concurrent Radiation and Immune Checkpoint Blockade,” Nature Cancer 3, no. 12 (2022): 1498–1512.

[134] K. L. Hung, M. G. Jones, I. T. Wong, et al., “Coordinated Inheritance of Extrachromosomal DNAs in Cancer Cells,” Nature 635, no. 8037 (2024): 201–209.

[135] E. Fiorini, A. Malinova, D. Schreyer, et al., “MYC ecDNA Promotes Intratumour Heterogeneity and Plasticity in PDAC,” Nature 640, no. 8059 (2025): 811–820.

[136] L. S. Pongor, C. W. Schultz, L. Rinaldi, et al., “Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and Is Associated With Worse Outcomes,” Cancer Discovery 13, no. 4 (2023): 928–949.

[137] O. S. Chapman, J. Luebeck, S. Sridhar, et al., “Circular Extrachromosomal DNA Promotes Tumor Heterogeneity in High-Risk Medulloblastoma,” Nature Genetics 55, no. 12 (2023): 2189–2199.

[138] G. Kildisiute, M. Kalyva, R. Elmentaite, et al., “Transcriptional Signals of Transformation in Human Cancer,” Genome Medicine 16, no. 1 (2024): 8.

[139] Z. Abdulrahman, R. C. Slieker, D. McGuire, M. J. P. Welters, M. I. E. van Poelgeest, and S. H. van der Burg, “Single-Cell Spatial Transcriptomics Unravels Cell States and Ecosystems Associated With Clinical Response to Immunotherapy,” Journal for ImmunoTherapy of Cancer 13, no. 3 (2025): e011308.

[140] Z. Zhang, X. Sun, Y. Liu, et al., “Spatial Transcriptome-Wide Profiling of Small Cell Lung Cancer Reveals Intra-Tumoral Molecular and Subtype Heterogeneity,” Advanced Science (Weinheim, Baden-Wurttemberg, Germany) 11, no. 31 (2024): e2402716.

[141] F. Peng, A. Sinjab, Y. Dai, et al., “Multimodal Spatial-Omics Reveal Co-Evolution of Alveolar Progenitors and Proinflammatory Niches in Progression of Lung Precursor Lesions,” Cancer Cell 44, no. 2 (2025): 321–339.e13.

[142] J. Kuang, G. Zhong, L. Zhao, X. Yuan, Y. Zhou, and J. Li, “Machine Learning Analysis Reveals Tumor Heterogeneity and Stromal-Immune Niches in Breast Cancer,” npj Digital Medicine 8, no. 1 (2025): 565.

[143] J. Hu, F. Liu, J. Zhang, et al., “Spatially Resolved Transcriptomic Analysis of the Adult Human Prostate,” Nature Genetics 57, no. 4 (2025): 922–933.

[144] S. Traynor, M. K. Jakobsen, T. M. Green, et al., “Single-Cell Sequencing Unveils Extensive Intratumoral Heterogeneity of Cancer/Testis Antigen Expression in Melanoma and Lung Cancer,” Journal for ImmunoTherapy of Cancer 12, no. 6 (2024): e008759.

[145] A. L. Smith, N. Denny, C. Chahrour, et al., “Enhancer Heterogeneity in Acute Lymphoblastic Leukemia Drives Differential Gene Expression in Patients,” Blood 146, no. 17 (2025): 2073–2087.

[146] D. Guo, K. Sheng, Q. Zhang, et al., “Single-Cell Transcriptomic Analysis Reveals the Landscape of Epithelial-Mesenchymal Transition Molecular Heterogeneity in Esophageal Squamous Cell Carcinoma,” Cancer Letters 587 (2024): 216723.

[147] Q. Zhong, X. Xiao, Y. Qiu, et al., “Protein Posttranslational Modifications in Health and Diseases: Functions, Regulatory Mechanisms, and Therapeutic Implications,” MedComm 4, no. 3 (2023): e261.

[148] S. Sharma, R. Ali, A. Bouska, et al., “Functional Genomics and Tumor Microenvironment Analysis Reveal Prognostic Biological Subtypes in Mantle Cell Lymphoma,” Nature Communications 16, no. 1 (2025): 9762.

[149] Y. Qu, X. Pei, J. Feng, et al., “Proteogenomic Analysis Identifies Clinically Relevant Subgroups of Collecting Duct Carcinoma,” Research (Wash D C) 8 (2025): 0859.

[150] B. Pai, S. I. Ramos, W. S. Cheng, et al., “Spatial Multiomics Defines a Shared Tumor Infiltrative Signature at the Resection Margin in High-Grade Gliomas,” Cancer Research 85, no. 21 (2025): 4233–4250.

[151] Y. Choi, M. Shim, S. H. Kim, et al., “Single-Cell Transcriptomics of the Myeloid Milieu Reveals an Angiogenic Niche in Triple-Negative Breast Cancer,” Experimental & Molecular Medicine 57, no. 11 (2025): 2487–2504.

[152] R. Szczepanski, “[Macrophotographic Documentation of Fungal Cultures in the Mycological Laboratory Using as an Example the Causative Agent of Tinea Imbricata. Possibilities for use and Technical Problems. IV. Evaluation of Results],” Mykosen 15, no. 12 (1972): 491–494, Makrofotografische Dokumentation von Polzkulturen im myokologischen Labor am Beispiel des Erregers der tinea imbricata. Verwendungsmoglichkeiten und technische Probleme. IV. Auswertung der Ergebnisse.

[153] Y. Tang, A. Xu, Z. Xu, et al., “Multi-Omics Analyses of the Heterogenous Immune Microenvironment in Triple-Negative Breast Cancer Implicate UQCRFS1 Potentiates Tumor Progression,” Experimental Hematology & Oncology 14, no. 1 (2025): 85.

[154] R. Jimenez-Castano and M. A. Nieto, “Epithelial-To-Mesenchymal Transition as a Central Driver of Tumor Cell Plasticity,” Nature Cancer 7, no. 4 (2026): 567–582.

[155] C. T. Mierke, “The Matrix Environmental and Cell Mechanical Properties Regulate Cell Migration and Contribute to the Invasive Phenotype of Cancer Cells,” Reports on Progress in Physics 82, no. 6 (2019): 064602.

[156] S. Safaei, R. Sajed, A. Shariftabrizi, et al., “Tumor Matrix Stiffness Provides Fertile Soil for Cancer Stem Cells,” Cancer Cell International 23, no. 1 (2023): 143.

[157] S. Wong, W. H. Guo, and Y. L. Wang, “Fibroblasts Probe Substrate Rigidity With Filopodia Extensions Before Occupying an Area,” Proceedings of the National Academy of Sciences of the United States of America 111, no. 48 (2014): 17176–17181.

[158] S. V. Plotnikov, A. M. Pasapera, B. Sabass, and C. M. Waterman, “Force Fluctuations Within Focal Adhesions Mediate ECM-Rigidity Sensing to Guide Directed Cell Migration,” Cell 151, no. 7 (2012): 1513–1527.

[159] M. Zhang and B. Zhang, “Extracellular Matrix Stiffness: Mechanisms in Tumor Progression and Therapeutic Potential in Cancer,” Experimental Hematology & Oncology 14, no. 1 (2025): 54.

[160] T. A. Al-Hilal, M. A. Chrysovergi, P. E. Grasberger, et al., “Durotaxis Is a Driver and Potential Therapeutic Target in Lung Fibrosis and Metastatic Pancreatic Cancer,” Nature Cell Biology 27, no. 9 (2025): 1543–1554.

[161] K. M. Pepin, R. L. Ehman, and K. P. McGee, “Magnetic Resonance Elastography (MRE) in Cancer: Technique, Analysis, and Applications,” Progress in Nuclear Magnetic Resonance Spectroscopy 90-91 (2015): 32–48.

[162] M. Khan, P. Kollenz, M. Fritzenschaft, et al., “Dimensional Memory in Glioblastoma Mechanics: Traction Force Analysis of Cells Cultured in 2D Versus 3D Collagen Environments,” Bioactive Materials 55 (2026): 515–528.

[163] P. Suarez-Meade, R. Whitehead, S. Rosenfeld, P. Schiapparelli, K. Konstantopoulos, and A. Quinones-Hinojosa, “Extracellular Matrix Stiffness Conditions Glioblastoma Cells for Long-Term Migration: Mechanical Memory as a Driver of Invasion and Recurrence in Glioblastoma,” Neuro-Oncology 28, no. 1 (2025): 19–37.

[164] F. Sauer, S. Grosser, M. Shahryari, et al., “Changes in Tissue Fluidity Predict Tumor Aggressiveness in Vivo,” Advanced Science (Weinheim, Baden-Wurttemberg, Germany) 10, no. 26 (2023): e2303523.

[165] S. Dupont, L. Morsut, M. Aragona, et al., “Role of YAP/TAZ in Mechanotransduction,” Nature 474, no. 7350 (2011): 179–183.

[166] B. M. Simões, R. Pedley, C. W. McCloskey, et al., “Anti-Progestin Therapy Targets Hallmarks of Breast Cancer Risk,” Nature 648, no. 8094 (2025): 736–745.

[167] Y. Kalukula, G. Ciccone, D. Mohammed, et al., “Unlocking the Therapeutic Potential of Cellular Mechanobiology,” Science Advances 11, no. 44 (2025): eaea6817.

[168] H. Su and M. Karin, “Collagen Architecture and Signaling Orchestrate Cancer Development,” Trends in Cancer 9, no. 9 (2023): 764–773.

[169] W. Fan, K. Adebowale, L. Vancza, et al., “Matrix Viscoelasticity Promotes Liver Cancer Progression in the Pre-Cirrhotic Liver,” Nature 626, no. 7999 (2024): 635–642.

[170] P. Tomecka, D. Kunachowicz, J. Gorczynska, et al., “Factors Determining Epithelial-Mesenchymal Transition in Cancer Progression,” International Journal of Molecular Sciences 25, no. 16 (2024): 8972.

[171] Z. M. Khan, A. Rossello-Martinez, and M. Mak, “Impact of Mechanical and Architectural Signals in the Tumor Microenvironment on Melanoma,” Advanced Healthcare Materials 14, no. 28 (2025): e01759.

[172] Y. Li, C. Huan, H. Sun, et al., “Spatial Transcriptomics and snRNA-seq Expose CAF Niches Orchestrating Dual Stromal-Immune Barriers in Hepatocellular Carcinoma,” Advanced science (Weinheim, Baden-Wurttemberg, Germany) 12, no. 48 (2025): e14661.

[173] R. Qin, Y. Zhang, J. Shi, et al., “TCR Catch Bonds Nonlinearly Control CD8 Cooperation to Shape T Cell Specificity,” Cell Research 35, no. 4 (2025): 265–283.

[174] C. E. Cornell, A. Chorlay, D. Krishnamurthy, N. R. Martin, L. Baldauf, and D. A. Fletcher, “Target Cell Cortical Tension Regulates Macrophage Trogocytosis,” Nature Cell Biology 27, no. 12 (2025): 2078–2088.

[175] M. Demicco, X. Z. Liu, K. Leithner, and S. M. Fendt, “Metabolic Heterogeneity in Cancer,” Nature Metabolism 6, no. 1 (2024): 18–38.

[176] Q. Cai, W. Deng, Y. Zou, Z. S. Chen, and H. Tang, “Histone Lactylation as a Driver of Metabolic Reprogramming and Immune Evasion,” Medical Review (2021) 5, no. 3 (2025): 256–259.

[177] D. Zhang, Z. Tang, H. Huang, et al., “Metabolic Regulation of Gene Expression by Histone Lactylation,” Nature 574, no. 7779 (2019): 575–580.

[178] E. Zlotorynski, “Gene Expression: ACSS2 Boosts Local Histone Acetylation,” Nature Reviews Molecular Cell Biology 18, no. 7 (2017): 405.

[179] P. Willnow and A. A. Teleman, “Nuclear Position and Local Acetyl-CoA Production Regulate Chromatin State,” Nature 630, no. 8016 (2024): 466–474.

[180] F. Hu, Z. Bai, K. Yan, Z. Zhang, and J. Zhou, “A Five-Gene Prognosis Model Based on Lysine β-Hydroxybutyrylation Site Genes to Predict the Survival and Therapy Response in Pancreatic Adenocarcinoma,” Heliyon 10, no. 14 (2024): e34284.

[181] F. Hu, Z. Bai, K. Yan, Z. Zhang, and J. Zhou, “A Five-Gene Prognosis Model Based on Lysine Beta-Hydroxybutyrylation Site Genes to Predict the Survival and Therapy Response in Pancreatic Adenocarcinoma,” Heliyon 10, no. 14 (2024): e34284.

[182] B. Perillo, A. Tramontano, A. Pezone, and A. Migliaccio, “LSD1: More Than Demethylation of Histone Lysine Residues,” Experimental & Molecular Medicine 52, no. 12 (2020): 1936–1947.

[183] J. P. Friedmann Angeli, D. V. Krysko, and M. Conrad, “Ferroptosis at the Crossroads of Cancer-Acquired Drug Resistance and Immune Evasion,” Nature Reviews Cancer 19, no. 7 (2019): 405–414.

[184] P. C. Hou, Y. H. Li, S. C. Lin, et al., “Hypoxia-Induced Downregulation of DUSP-2 Phosphatase Drives Colon Cancer Stemness,” Cancer Research 77, no. 16 (2017): 4305–4316.

[185] H. Lee, B. Kim, J. Park, et al., “Cancer Stem Cells: Landscape, Challenges and Emerging Therapeutic Innovations,” Signal Transduction and Targeted Therapy 10, no. 1 (2025): 248.

[186] A. Suvac, J. Ashton, and R. G. Bristow, “Tumour Hypoxia in Driving Genomic Instability and Tumour Evolution,” Nature Reviews Cancer 25, no. 3 (2025): 167–188.

[187] M. Springer, Z. A. Burakgazi, A. Domukhovska, et al., “HIF-1alpha-Mediated Disruption of Cellular Junctions: The Impact of Hypoxia on the Tumor Microenvironment and Invasion,” International Journal of Molecular Sciences 26, no. 11 (2025): 5101.

[188] E. Richiardone, M. V. Giolito, and R. Al Roumi, “Acidosis Overrides Molecular Heterogeneity to Shape Therapeutically Targetable Metabolic Phenotypes in Colon Cancers,” Cancer Letters 613 (2025): 217512.

[189] H. Chen, M. Li, F. Xie, et al., “A Novel Protein cPFKFB4 Encoded by hsa_circ_0065394 Strengthens PKM2-Mediated Glucose Metabolic Reprogramming to Facilitate Pancreatic Cancer Progression Under Hypoxia,” Molecular Cancer 24, no. 1 (2025): 285.

[190] R. Missiaen, N. P. Lesner, and M. C. Simon, “HIF: A Master Regulator of Nutrient Availability and Metabolic Cross-Talk in the Tumor Microenvironment,” Embo Journal 42, no. 6 (2023): e112067.

[191] H. Li, C. Liu, R. Li, et al., “AARS1 and AARS2 Sense L-Lactate to Regulate cGAS as Global Lysine Lactyltransferases,” Nature 634, no. 8036 (2024): 1229–1237.

[192] C. L. Roland, T. Arumugam, D. Deng, et al., “Cell Surface Lactate Receptor GPR81 Is Crucial for Cancer Cell Survival,” Cancer Research 74, no. 18 (2014): 5301–5310.

[193] S. Ishihara, K. Hata, K. Hirose, et al., “The Lactate Sensor GPR81 Regulates Glycolysis and Tumor Growth of Breast Cancer,” Scientific Reports 12, no. 1 (2022): 6261.

[194] T. P. Brown and V. Ganapathy, “Lactate/GPR81 Signaling and Proton Motive Force in Cancer: Role in Angiogenesis, Immune Escape, Nutrition, and Warburg Phenomenon,” Pharmacology & Therapeutics 206 (2020): 107451.

[195] M. Parlani, C. Jorgez, and P. Friedl, “Plasticity of Cancer Invasion and Energy Metabolism,” Trends in Cell Biology 33, no. 5 (2023): 388–402.

[196] G. Hoover, S. Gilbert, O. Curley, et al., “Nerve-to-Cancer Transfer of Mitochondria During Cancer Metastasis,” Nature 644, no. 8075 (2025): 252–262.

[197] C. T. Kureshi and S. K. Dougan, “Cytokines in Cancer,” Cancer Cell 43, no. 1 (2025): 15–35.

[198] T. R. Mempel, J. K. Lill, and L. M. Altenburger, “How Chemokines Organize the Tumour Microenvironment,” Nature Reviews Cancer 24, no. 1 (2024): 28–50.

[199] N. Goto, P. M. K. Westcott, S. Goto, et al., “SOX17 Enables Immune Evasion of Early Colorectal Adenomas and Cancers,” Nature 627, no. 8004 (2024): 636–645.

[200] X. Shi, J. Yang, S. Deng, et al., “TGF-Beta Signaling in the Tumor Metabolic Microenvironment and Targeted Therapies,” Journal of hematology & oncology 15, no. 1 (2022): 135.

[201] B. M. Lehrich, E. R. Delgado, T. M. Yasaka, et al., “Precision Targeting of Beta-Catenin Induces Tumor Reprogramming and Immunity in Hepatocellular Cancers,” Nature Communications 16, no. 1 (2025): 5009.

[202] Q. J. Wu, T. N. Zhang, H. H. Chen, et al., “The Sirtuin Family in Health and Disease,” Signal Transduction and Targeted Therapy 7, no. 1 (2022): 402.

[203] H. Lee, B. Kim, J. Park, et al., “Cancer Stem Cells: Landscape, Challenges and Emerging Therapeutic Innovations,” Signal Transduction and Targeted Therapy 10, no. 1 (2025): 248.

[204] R. Noberini, G. Robusti, A. Vai, et al., “A Histone-Centric Multi-Omics Study Shows That Increased H3K4 Methylation Sustains Triple-Negative Breast Cancer Phenotypes,” Nature Communications 16, no. 1 (2025): 8716.

[205] J. Xiao, R. Niu, and F. Zhao, “Single-Cell and Spatial Transcriptome Analysis Revealed Cellular Heterogeneity of Glycosyltransferases in Cervical Cancer, and Identified GALNT3-Negative Epithelial Cells as a Protective Factor: A Retrospective Cohort Study Based on Public Database,” International Journal of Surgery 111, no. 7 (2025): 4263–4278.

[206] M. Tao, W. Liu, J. Chen, et al., “Transcriptome Landscape of Cancer-Associated Fibroblasts in Human PDAC,” Advanced Science (Weinheim, Baden-Wurttemberg, Germany) 12, no. 20 (2025): e2415196.

[207] Y. Wu, S. Li, H. Yu, et al., “Integrative Single-Cell and Spatial Transcriptomics Analysis Reveals ECM-Remodeling Cancer-Associated Fibroblast-Derived POSTN as a Key Mediator in Pancreatic Ductal Adenocarcinoma Progression,” International Journal of Biological Sciences 21, no. 8 (2025): 3573–3596.

[208] W. Xu, J. Weng, Y. Zhao, et al., “FMO2(+) Cancer-Associated Fibroblasts Sensitize Anti-PD-1 Therapy in Patients With Hepatocellular Carcinoma,” Journal for ImmunoTherapy of Cancer 13, no. 5 (2025): e011648.

[209] Y. Gao, X. Zhang, S. Xia, et al., “Spatial Multi-Omics Reveals the Potential Involvement of SPP1(+) Fibroblasts in Determining Metabolic Heterogeneity and Promoting Metastatic Growth of Colorectal Cancer Liver Metastasis,” Molecular Therapy 33, no. 8 (2025): 3680–3700.

[210] H. Jieun Kim, T. Ruan, and A. Swarbrick, “Pan-Cancer Spatial Profiling Reveals Conserved Subtypes and Niches of Cancer-Associated Fibroblasts,” Cancer Research 85, no. 14 (2025): 2555–2557.

[211] Y. Liu, A. Sinjab, J. Min, et al., “Conserved Spatial Subtypes and Cellular Neighborhoods of Cancer-Associated Fibroblasts Revealed by Single-Cell Spatial Multi-Omics,” Cancer Cell 43, no. 5 (2025): 905–924.e6.

[212] C. Chu, F. Li, Z. Zhang, et al., “Immunoregulatory Roles of Tumor-Originated Pericytes Identified by Single-Cell Analysis in Glioblastoma,” Advanced science (Weinheim, Baden-Wurttemberg, Germany) 12, no. 47 (2025): e11856.

[213] M. Liu, G. Bertolazzi, S. Sridhar, et al., “Spatially-Resolved Transcriptomics Reveal Macrophage Heterogeneity and Prognostic Significance in Diffuse Large B-Cell Lymphoma,” Nature Communications 15, no. 1 (2024): 2113.

[214] X. Qiu, T. Zhou, S. Li, et al., “Spatial Single-Cell Protein Landscape Reveals Vimentin(high) Macrophages as Immune-Suppressive in the Microenvironment of Hepatocellular Carcinoma,” Nature Cancer 5, no. 10 (2024): 1557–1578.

[215] Y. Fang, X. Xu, R. Lu, et al., “TEAD3 + High-Risk Melanoma Cells Crosstalk With GAS6 + Macrophages via the GAS6-TYRO3 Ligand-Receptor Axis to Modulate Propionate Metabolism and Drive Melanoma Progression,” Journal of Experimental & Clinical Cancer Research 44, no. 1 (2025): 279.

[216] G. Dunsmore, W. Guo, Z. Li, et al., “Timing and Location Dictate Monocyte Fate and Their Transition to Tumor-Associated Macrophages,” Science Immunology 9, no. 97 (2024): eadk3981.

[217] Y. Chu, E. Dai, Y. Li, et al., “Pan-Cancer T Cell Atlas Links a Cellular Stress Response State to Immunotherapy Resistance,” Nature Medicine 29, no. 6 (2023): 1550–1562.

[218] Y. Zhang, C. Zuo, Y. Li, et al., “Single-Cell Characterization of Infiltrating T Cells Identifies Novel Targets for Gallbladder Cancer Immunotherapy,” Cancer Letters 586 (2024): 216675.

[219] P. Zhou, H. Shi, H. Huang, et al., “Single-Cell CRISPR Screens in Vivo Map T Cell Fate Regulomes in Cancer,” Nature 624, no. 7990 (2023): 154–163.

[220] J. Ma, Y. Wu, L. Ma, et al., “A Blueprint for Tumor-Infiltrating B Cells Across Human Cancers,” Science 384, no. 6695 (2024): eadj4857.

[221] Y. Yang, X. Chen, J. Pan, et al., “Pan-Cancer Single-Cell Dissection Reveals Phenotypically Distinct B Cell Subtypes,” Cell 187, no. 17 (2024): 4790–4811.e22.

[222] J. Oh, J. Hoelzl, J. C. T. Carlson, et al., “Spatial Analysis Identifies DC Niches as Predictors of Pembrolizumab Therapy in Head and Neck Squamous Cell Cancer,” Cell Reports Medicine 6, no. 5 (2025): 102100.

[223] F. Tang, J. Li, L. Qi, et al., “A Pan-Cancer Single-Cell Panorama of Human Natural Killer Cells,” Cell 186, no. 19 (2023): 4235–4251.e20.

[224] L. Wang, G. Shen, G. Xie, et al., “Targeting Mast Cell Activation and MIF-Mediated Remodelling Enhances Chemotherapy Response in Pancreatic Cancer,” Advanced science (Weinheim, Baden-Wurttemberg, Germany) 12, no. 48 (2025): e09930.

[225] Y. Lu, L. Xu, W. Chen, et al., “Intrahepatic Microbial Heterogeneity in Multifocal Hepatocellular Carcinoma and Its Association With Host Genomic and Transcriptomic Alterations,” Cancer Discovery 15, no. 8 (2025): 1630–1648.

[226] F. Du, L. Xiao, W. Guojun, et al., “Glutamine Metabolism and Ammonia Death: Targeted Modulation for Enhanced Cancer Immunotherapy,” Frontiers in Immunology 16 (2025): 1643017.

[227] Y. Chhabra and A. T. Weeraratna, “Fibroblasts in Cancer: Unity in Heterogeneity,” Cell 186, no. 8 (2023): 1580–1609.

[228] G. Fan, B. Yu, L. Tang, et al., “TSPAN8(+) Myofibroblastic Cancer-Associated Fibroblasts Promote Chemoresistance in Patients With Breast Cancer,” Science Translational Medicine 16, no. 741 (2024): eadj5705.

[229] H. Croizer, R. Mhaidly, Y. Kieffer, et al., “Deciphering the Spatial Landscape and Plasticity of Immunosuppressive Fibroblasts in Breast Cancer,” Nature Communications 15, no. 1 (2024): 2806.

[230] J. Yu, Z. Xu, J. Guo, K. Yang, J. Zheng, and X. Sun, “Tumor-Associated Macrophages (TAMs) Depend on MMP1 for Their Cancer-Promoting Role,” Cell Death Discovery 7, no. 1 (2021): 343.

[231] K. Kainulainen, E. A. Niskanen, J. Kinnunen, et al., “Secreted Factors From M1 Macrophages Drive Prostate Cancer Stem Cell Plasticity by Upregulating NANOG, SOX2, and CD44 Through NFkappaB-Signaling,” Oncoimmunology 13, no. 1 (2024): 2393442.

[232] X. Meng, Y. Zheng, L. Zhang, P. Liu, Z. Liu, and Y. He, “Single-Cell Analyses Reveal the Metabolic Heterogeneity and Plasticity of the Tumor Microenvironment During Head and Neck Squamous Cell Carcinoma Progression,” Cancer Research 84, no. 15 (2024): 2468–2483.

[233] D. J. Kloosterman and L. Akkari, “Macrophages at the Interface of the Co-Evolving Cancer Ecosystem,” Cell 186, no. 8 (2023): 1627–1651.

[234] L. Liu, S. Zhang, Y. Ren, et al., “Macrophage-Derived Exosomes in Cancer: A Double-Edged Sword With Therapeutic Potential,” Journal of Nanobiotechnology 23, no. 1 (2025): 319.

[235] B. Kruse, A. C. Buzzai, N. Shridhar, et al., “CD4(+) T Cell-Induced Inflammatory Cell Death Controls Immune-Evasive Tumours,” Nature 618, no. 7967 (2023): 1033–1040.

[236] A. S. Ireland and T. G. Oliver, “Neutrophils Create an ImpeNETrable Shield Between Tumor and Cytotoxic Immune Cells,” Immunity 52, no. 5 (2020): 729–731.

[237] D. Lambrechts, E. Wauters, B. Boeckx, et al., “Phenotype Molding of Stromal Cells in the Lung Tumor Microenvironment,” Nature Medicine 24, no. 8 (2018): 1277–1289.

[238] Y. Ito, D. Pan, W. Zhang, et al., “Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell-Secreted Cytokines,” Cancer Discovery 13, no. 5 (2023): 1186–1209.

[239] Y. Abe, J. Zenkoh, A. Kanai, et al., “Distinct Follicular T Cell Subsets Regulate Lymphoma Progression and Outcomes,” Cancer Cell 43, no. 10 (2025): 1850–1865.e11.

[240] E. Fitzsimons, D. Qian, A. Enica, et al., “A Pan-Cancer Single-Cell RNA-seq Atlas of Intratumoral B Cells,” Cancer Cell 42, no. 10 (2024): 1784–1797.e4.

[241] L. Henriques-Oliveira, A. R. Altman, I. Kurochkin, et al., “Anchored Screening Identifies Transcription Factor Blueprints Underlying Dendritic Cell Diversity and Subset-Specific Anti-Tumor Immunity,” Immunity 58, no. 10 (2025): 2419–2438.e13.

[242] L. Rebuffet, J. E. Melsen, B. Escaliere, et al., “High-Dimensional Single-Cell Analysis of Human Natural Killer Cell Heterogeneity,” Nature Immunology 25, no. 8 (2024): 1474–1488.

[243] J. P. Li, Y. J. Liu, Y. Zhang, et al., “Comprehensive Analytical Approach Identifies a Subtype of CTCF+ Tumor-Associated Neutrophils Associated With CRC Development and as a Biomarker for Immunotherapy,” International Journal of Biological Sciences 21, no. 12 (2025): 5305–5327.

[244] J. M. N. Teo, Z. Chen, W. Chen, et al., “Tumor-Associated Neutrophils Attenuate the Immunosensitivity of Hepatocellular Carcinoma,” Journal of Experimental Medicine 222, no. 1 (2025): e20241442.

[245] E. Riquelme, Y. Zhang, L. Zhang, et al., “Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes,” Cell 178, no. 4 (2019): 795–806.e12.

[246] Q. Q. Liu, Z. K. Dong, Y. F. Wang, and W. L. Jin, “Reprogramming Neural-Tumor Crosstalk: Emerging Therapeutic Dimensions and Targeting Strategies,” Military Medical Research 12, no. 1 (2025): 73..

[247] Y. Du, X. Ding, and Y. Ye, “The Spatial Multi-Omics Revolution in Cancer Therapy: Precision Redefined,” Cell Reports Medicine 5, no. 9 (2024): 101740.

[248] R. A. Burrell and C. Swanton, “Tumour Heterogeneity and the Evolution of Polyclonal Drug Resistance,” Molecular Oncology 8, no. 6 (2014): 1095–1111.

[249] C. C. Bell and O. Gilan, “Principles and Mechanisms of Non-Genetic Resistance in Cancer,” British Journal of Cancer 122, no. 4 (2020): 465–472.

[250] M. Mikubo, Y. Inoue, G. Liu, and M. S. Tsao, “Mechanism of Drug Tolerant Persister Cancer Cells: The Landscape and Clinical Implication for Therapy,” Journal of Thoracic Oncology 16, no. 11 (2021): 1798–1809.

[251] M. Tanaka, L. Lum, K. H. Hu, et al., “Tumor Cell Heterogeneity Drives Spatial Organization of the Intratumoral Immune Response,” Journal of Experimental Medicine 222, no. 6 (2025): e20242282.

[252] Z. Liu, Z. Yang, J. Wu, et al., “A Single-Cell Atlas Reveals Immune Heterogeneity in Anti-PD-1-Treated Non-Small Cell Lung Cancer,” Cell 188, no. 11 (2025): 3081–3096.e19.

[253] M. Benguigui, T. J. Cooper, P. Kalkar, et al., “Interferon-Stimulated Neutrophils as a Predictor of Immunotherapy Response,” Cancer Cell 42, no. 2 (2024): 253–265.e12.

[254] Y. Li, R. Chen, L. Zhang, et al., “Intra-Tumor DKK1 and CALML5 Heterogeneity as a Novel Biomarker for Prognosis and Immunotherapy Response in Head and Neck Squamous Cell Carcinoma,” Current Molecular Pharmacology 18, no. 1 (2025): 6–21.

[255] A. Lyu, Z. Fan, M. Clark, et al., “Evolution of Myeloid-Mediated Immunotherapy Resistance in Prostate Cancer,” Nature 637, no. 8048 (2025): 1207–1217.

[256] M. Shakiba and D. A. Tuveson, “Macrophages and Fibroblasts as Regulators of the Immune Response in Pancreatic Cancer,” Nature Immunology 26, no. 5 (2025): 678–691.

[257] B. H. Jenkins, I. Tracy, M. Rodrigues, et al., “Single Cell and Spatial Analysis of Immune-Hot and Immune-Cold Tumours Identifies Fibroblast Subtypes Associated With Distinct Immunological Niches and Positive Immunotherapy Response,” Molecular Cancer 24, no. 1 (2025): 3.

[258] J. Li, H. Liu, Q. Guo, et al., “Single-Cell Screens Identify ADAM12 as a Fibroblast Checkpoint Impeding Anti-Tumor Immunity,” Cancer Cell 44, no. 2 (2026): 424–442.e14.

[259] R. Qi, Y. Bai, K. Li, et al., “Cancer-Associated Fibroblasts Suppress Ferroptosis and Induce Gemcitabine Resistance in Pancreatic Cancer Cells by Secreting Exosome-Derived ACSL4-Targeting miRNAs,” Drug Resistance Updates 68 (2023): 100960.

[260] C. Li, A. F. Teixeira, H. J. Zhu, and P. Ten Dijke, “Cancer Associated-Fibroblast-Derived Exosomes in Cancer Progression,” Molecular Cancer 20, no. 1 (2021): 154.

[261] Q. Wu, L. Zhou, D. Lv, X. Zhu, and H. Tang, “Exosome-Mediated Communication in the Tumor Microenvironment Contributes to Hepatocellular Carcinoma Development and Progression,” Journal of Hematology & Oncology 12, no. 1 (2019): 53.

[262] X. Yao, H. Yang, S. Guo, et al., “Radiation-Triggerable Bioreactors Enable Bioenergetic Reprograming of Cancer Stem Cell Plasticity via Targeted Arginine Metabolism Disruption for Augmented Radio-Immunotherapy,” Biomaterials 322 (2025): 123391.

[263] M. Borgeaud, T. Olivier, J. Bar, et al., “Personalized Care for Patients With EGFR-Mutant Nonsmall Cell Lung Cancer: Navigating Early to Advanced Disease Management,” CA: A Cancer Journal for Clinicians 75, no. 5 (2025): 387–409.

[264] H. Wang, N. Gao, L. Wang, et al., “Transformation From EGFR-Mutant Lung Adenocarcinoma to Small-Cell Lung Cancer: From Clonal Evolution to Lineage Reprogramming,” Cancer Treatment Reviews 141 (2025): 103044.

[265] N. Chatterjee and T. G. Bivona, “Polytherapy and Targeted Cancer Drug Resistance,” Trends in Cancer 5, no. 3 (2019): 170–182.

[266] A. M. Schram, M. T. Chang, P. Jonsson, and A. Drilon, “Fusions in Solid Tumours: Diagnostic Strategies, Targeted Therapy, and Acquired Resistance,” Nature Reviews Clinical Oncology 14, no. 12 (2017): 735–748.

[267] B. Kang, M. B. Zheng, P. Song, et al., “Subcellular-Scale Drug Transport via Ultrasound-Degradable Mesoporous Nanosilicon to Bypass Cancer Drug Resistance,” Small 13, no. 20 (2017): 1604228.

[268] M. A. Rubin, R. G. Bristow, P. D. Thienger, C. Dive, and M. Imielinski, “Impact of Lineage Plasticity to and From a Neuroendocrine Phenotype on Progression and Response in Prostate and Lung Cancers,” Molecular Cell 80, no. 4 (2020): 562–577.

[269] Y. Liu, Y. Dai, and L. Wang, “Spatial Omics at the Forefront: Emerging Technologies, Analytical Innovations, and Clinical Applications,” Cancer Cell 44, no. 1 (2026): 24–49.

[270] Y. M. Choi, D. Na, G. Yoon, et al., “Prediction of Patient Drug Response via 3D Bioprinted Gastric Cancer Model Utilized Patient-Derived Tissue Laden Tissue-Specific Bioink,” Advanced science (Weinheim, Baden-Wurttemberg, Germany) 12, no. 10 (2025): e2411769.

[271] J. Wang, J. Zhang, X. Dai, C. Yan, and C. Fang, “Computational Models for Pan-Cancer Classification Based on Multi-Omics Data,” Frontiers in Genetics 16 (2025): 1667325.

[272] D. Tran, V. D. Pham, H. Nguyen, et al., “DSCC: Disease Subtyping Using Spectral Clustering and Community Detection From Consensus Networks,” Briefings in Bioinformatics 26, no. 6 (2025): bbaf600.

[273] X. Huang, S. Huang, C. Reina, et al., “Single-Cell Multi-Omics and Machine Learning for Dissecting Stemness in Cancer,” Briefings in Bioinformatics 26, no. 5 (2025): bbaf566.

[274] Y. Zhang, G. Xiang, A. Y. Jiang, et al., “MetaTiME Integrates Single-Cell Gene Expression to Characterize the Meta-Components of the Tumor Immune Microenvironment,” Nature Communications 14, no. 1 (2023): 2634.

[275] X. Song, J. Ji, J. H. Rothstein, et al., “MiXcan: A Framework for Cell-Type-Aware Transcriptome-Wide Association Studies With an Application to Breast Cancer,” Nature Communications 14, no. 1 (2023): 377.

[276] C. Saillard, F. Delecourt, B. Schmauch, et al., “Pacpaint: A Histology-Based Deep Learning Model Uncovers the Extensive Intratumor Molecular Heterogeneity of Pancreatic Adenocarcinoma,” Nature Communications 14, no. 1 (2023): 3459.

[277] Y. Feng, T. Yang, J. Zhu, et al., “Spatial Analysis With SPIAT and spaSim to Characterize and Simulate Tissue Microenvironments,” Nature Communications 14, no. 1 (2023): 2697.

[278] M. Edrisi, X. Huang, H. A. Ogilvie, and L. Nakhleh, “Accurate Integration of Single-Cell DNA and RNA for Analyzing Intratumor Heterogeneity Using MaCroDNA,” Nature Communications 14, no. 1 (2023): 8262.

[279] S. He, Y. Jin, A. Nazaret, et al., “Starfysh Integrates Spatial Transcriptomic and Histologic Data to Reveal Heterogeneous Tumor-Immune Hubs,” Nature Biotechnology 43, no. 2 (2025): 223–235.

[280] C. Yang, M. Gao, X. Zhang, H. Yu, and C. Deng, “Multi-Modal Single-Cell Platform for Nanoparticle-Enhanced Time-Series Metabolic Profiles of CD8(+) T Cell Exhaustion in Tumor Immunosurveillance,” Journal of Nanobiotechnology 23, no. 1 (2025): 701.

[281] W. Liu, N. Liao, Y. Lei, et al., “Detachable DNA Assembly Module to Dissect Tumor Cells Heterogeneity via RNA Pinpoint Screening,” Advanced Science (Weinheim, Baden-Wurttemberg, Germany) 11, no. 46 (2024): e2401253.

[282] A. E. Bura, C. Caussette, M. Gueguinou, et al., “Investigation of the Heterogeneity of Cancer Cells Using Single Cell Ca(2+) Profiling,” Cell Communication and Signaling 23, no. 1 (2025): 413.

[283] B. Tan, S. Li, M. Wang, and S. C. Li, “CeiTEA: Adaptive Hierarchy of Single Cells With Topological Entropy,” Advanced Science (Weinheim, Baden-Wurttemberg, Germany) 12, no. 26 (2025): e2503539.

[284] D. Zeng, Y. Yu, W. Qiu, et al., “Immunotyping the Tumor Microenvironment Reveals Molecular Heterogeneity for Personalized Immunotherapy in Cancer,” Advanced Science (Weinheim, Baden-Wurttemberg, Germany) 12, no. 25 (2025): e2417593.

[285] Y. Chen, J. Bai, J. Wang, et al., “MSFusion: A Multi-Source Hybrid Feature Fusion Network for Accurate Grading of Invasive Breast Cancer Using H&E-Stained Histopathological Images,” Medical Image Analysis 104 (2025): 103633.

[286] C. Zuo, J. Xia, Y. Xu, et al., “stClinic Dissects Clinically Relevant Niches by Integrating Spatial Multi-Slice Multi-Omics Data in Dynamic Graphs,” Nature Communications 16, no. 1 (2025): 5317.

[287] J. Young, J. Inamo, Z. Caterer, R. Krishna, and F. Zhang, “CellPhenoX: An Explainable Machine Learning Method for Identifying Cell Phenotypes To Predict Clinical Outcomes From Single-Cell Multi-Omics,” Advanced Science (Weinheim, Baden-Wurttemberg, Germany) 12, no. 42 (2025): e03289.

[288] J. Kang, P. Chouvardas, A. Maalouf, et al., “Multi-Layer Stratified Oncology Platform Utilizing Transcriptomics, Prostate Cancer Organoids, and Modeling of Drug Response,” Journal of Experimental & Clinical Cancer Research 44, no. 1 (2025): 290.

[289] L. Du, Z. Zheng, K. Zhang, et al., “Exploring Personalized Prediction of Clinical Chemotherapy Efficacy and Revealing Tumor Heterogeneity Using Patient-Derived 3D Bioprinting Gastric Cancer Models,” Molecular Cancer 24, no. 1 (2025): 259.

[290] F. Huber, M. Arnaud, B. J. Stevenson, et al., “A Comprehensive Proteogenomic Pipeline for Neoantigen Discovery to Advance Personalized Cancer Immunotherapy,” Nature Biotechnology 43, no. 8 (2025): 1360–1372.

[291] A. R. Ramos, G. Bregni, N. Gillet, et al., “SHIP2-PLK1 Crosstalk Promotes Sensitivity to Dual Inhibition in Esophageal Squamous Cell Carcinoma,” Molecular Cancer 24, no. 1 (2025): 280.

[292] J. Zang, Z. Ren, H. Wang, et al., “Emerging Nanozyme Strategies for Precision Breast Cancer Treatment,” Advanced Science (Weinheim, Baden-Wurttemberg, Germany) 12, no. 46 (2025): e14085.

[293] X. Deng, X. Liu, and L. Zhao, “Multifunctional Nanoplatforms for Tumor Microenvironment Remodeling: Toward Precision and Intelligent Cancer Therapy,” Materials Today Bio 35 (2025): 102385.

[294] J. Lv, L. X. Xu, Z. X. Li, et al., “Longitudinal On-Treatment Circulating Tumor DNA as a Biomarker for Real-Time Dynamic Risk Monitoring in Cancer Patients: The EP-SEASON Study,” Cancer Cell 42, no. 8 (2024): 1401–1414.e4.

[295] B. Liu, Z. Hu, J. Ran, et al., “The Circulating Tumor DNA (ctDNA) Alteration Level Predicts Therapeutic Response in Metastatic Breast Cancer: Novel Prognostic Indexes Based on ctDNA,” Breast 65 (2022): 116–123.

[296] D. S. Wang, Z. X. Liu, Y. X. Lu, et al., “Liquid Biopsies to Track Trastuzumab Resistance in Metastatic HER2-Positive Gastric Cancer,” Gut 68, no. 7 (2019): 1152–1161.

[297] E. Katsoulakis, Q. Wang, H. Wu, et al., “Digital Twins for Health: A Scoping Review,” npj Digital Medicine 7, no. 1 (2024): 77.

[298] B. Meghdadi, W. N. Al-Holou, A. J. Scott, et al., “Digital Twins for in Vivo Metabolic Flux Estimations in Patients With Brain Cancer,” Cell Metabolism 38, no. 1 (2026): 228–246.e17.

[299] D. Camacho-Gomez, C. Borau, J. M. Garcia-Aznar, M. J. Gomez-Benito, M. Girolami, and M. A. Perez, “Physics-Informed Machine Learning Digital Twin for Reconstructing Prostate Cancer Tumor Growth via PSA Tests,” npj Digital Medicine 8, no. 1 (2025): 485.

[300] K. R. Scibilia, K. Gallagher, M. A. Masud, et al., “Mathematical Oncology: How Modeling Is Transforming Clinical Decision-Making,” Cancer Research 85, no. 24 (2025): 4866–4879.

[301] M. Springer, Z. A. Burakgazi, A. Domukhovska, et al., “HIF-1α-Mediated Disruption of Cellular Junctions: The Impact of Hypoxia on the Tumor Microenvironment and Invasion,” International Journal of Molecular Sciences 26, no. 11 (2025): 5101.

Rights & permissions

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.